Navigation Links
Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology

PETACH TIKVA, Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange Exchange, proceeds with the development of its third drug CF502; this is in addition to CF101, which is currently in clinical trials and CF102, which is in preclinical phases. This weekend Can-Fite will present at the EUALR annual congress of rheumatology in-vitro and in vivo study results showing effective anti-inflammatory activity for CF502. The EUALR congress is highly regarded and attracts global leaders in the Rheumatology arena.

The chemical structure of CF502 differs from that of the Company's first two drugs CF101 and CF102, and is characterized by higher affinity and selectivity to the A3 adenosine receptor, which is targeted by the Can-Fite's drugs. The drug attacks inflammatory cells and leads to programmed cell death (apoptosis) and suppression of the inflammatory process. Can-Fite is using human cells to investigate the effects and mechanism of action of CF502. The Company is currently finalizing the development of CF502 synthesis process, before entering preclinical and clinical development phases.

Can-Fite will present at the rheumatology congress in-vitro data showing that CF502 specifically targets inflammatory cells and does not affect healthy cells, and will also present the drug's molecular mechanism of action. In addition in vivo data showing marked anti-inflammatory effects of CF502 will be reported. The Company will also present new data on the expression of A3 adenosine receptor in various autoimmune diseases. High expression of this receptor is directly correlated with response of inflammatory cells to this drug.

Prof. Pnina Fishman, CEO of Can-Fite: "I am pleased with the rapid progress in the CF502 development program and with the in-vitro and in vivo trial results showing impressive anti-inflammatory activity for this drug. Elucidation of CF502 mechanism of action and the ability to examine this activity in human cells improve the chances that this drug can offer effective treatment for patients."

CF502, which is being developed by Can-Fite, became part of the development pipeline after Can-Fite had signed a prestigious agreement with the NIH, the leading research institute in the US. Under this agreement, titled CRADA, Can-Fite now cooperates with the laboratory of Prof. Jacobson, a worldwide leading scientist in the field of A3 adenosine receptor agonists and antagonists. Can-Fite is currently in negotiations with the NIH for the licensing of the CF502 molecule.

In addition to CF502, Can-Fite's development pipeline also includes two other drugs, CF101 which is being evaluated for rheumatoid arthritis, dry eye syndrome and psoriasis in phase I clinical trials, and CF102 which is intended for the treatment of liver cancer and hepatitis B. The Company's first commercial agreement was signed with the Japanese Seikagaku Corporation during development of CF101, under the terms of which Can-Fite has already received about USD 5 million.

CAN-FITE BIOPHARMA LTD is a public company traded on the Tel Aviv Stock Exchange. The Company, which commenced business activity in 2000, was founded by researcher Prof. Pnina Fishman and patent attorney Dr. Ilan Cohn. The Company focuses on the development of molecule-based drugs that inhibit the development of cancer or inflammatory cells. The market for the company's drugs is estimated at billions of dollars.

Contact

Can-Fite BioPharma
Pnina Fishman, Ph.D., +972-3-9241114
Chief Executive Officer
Fax: +972-3-9249378
pnina@canfite.co.il
http://www.canfite.com/


'"/>




Related medicine technology :

1. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
2. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
3. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
4. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
5. CuraGen Presents Update on Clinical Development Program for Belinostat
6. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting
9. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
10. Biomira Selects PX-866 as Clinical Development Candidate and Presents Promising Preclinical Data at AACR
11. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... in the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity ... a rare and deadly chromosome abnormality. , After struggling since birth with several ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
Breaking Medicine News(10 mins):